C4 Therapeutics, Inc.

NASDAQ:CCCC

Biotechnology

Healthcare
$2.48 +2.06%

+$0.08 today

Market cap
$325.01M
Beta
2.93
P/E (TTM)
-4.9
EPS (TTM)
-$0.82
52W Low $1.36High $4.60

Volume 2.75M

Average 2.76M

Returns on capital

C4 Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-40.9%

avg -22.9%

ROIC

-31.4%

avg -29.2%

ROA

-29.2%

avg -24.6%

Analysis

ROA is currently the strongest return metric at -29.2% versus its period average of -24.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Andrew J. Hirsch

Chief Executive Officer, President & DirectorUSD 1.38M55——

Leonard J. Reyno

Chief Medical OfficerUSD 1.03M64——

Kendra Adams

Principal Accounting Officer, CFO, Head of Corporate Affairs & TreasurerUSD 869.51K49337.15K0.41%

Kenneth C. Anderson

Co-Founder, Independent Director & Member of Scientific Advisory BoardUSD 45.75K75——

Christopher Nasveschuk

Senior Vice President of Chemistry————

Isabel Chiu

Senior Vice President of Strategic Alliances & Business Development————

Nathanael S. Gray

Co-Founder & Member of Scientific Advisory Board————

Roy Pollock

Senior Vice President of Biological Sciences————

Courtney Solberg

Senior Manager of Investor Relations————

Kelly Schick

Chief People Officer—46299.88K0.36%

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 12, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

2

$144,686.59

Net Transaction Value

−$144,686.59

Net selling

Most Active

Adams Kendra

1 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 12, 26

Adams Kendra

Direct

Sell$122.5K
Jan 16, 26

REYNO LEONARD

Direct

Sell$22.2K

Summary

Insiders reported 0 buys worth $0.00 and 2 sells worth $144,686.59 over the last 12 months. That adds up to net selling of $144,686.59. Adams Kendra was the most active insider with 1 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A4 analysts
RevenueN/AN/A+5.0%
+135.8% (5yr)5 analysts
Net IncomeN/AN/AN/A
N/A5 analysts
EBITN/AN/AN/A
N/A5 analysts

Analysis

Recent growth has been strongest in Revenue at +5.0% over three years. Forward estimates point to Revenue at +135.8% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does C4 Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about CCCC's management, answered from reported figures.

Who manages CCCC?

C4 Therapeutics, Inc. (CCCC) lists 10 active executives. The top listed executive is Christopher Nasveschuk, Senior Vice President of Chemistry.

Are CCCC insiders buying or selling?

Recent insider activity shows net buying of $9.08M.